You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD32b

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

Terminated
Has Results
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +5 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • anti-CD19 CAR NK cells
  • (no location specified)
Dec 21, 2022

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • U-CAR-T Cells (LstCAR019)
  • Kunming, Yunnan, China
    Kunming Hope of Health Hospital
Nov 27, 2022

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • UCAR-T Cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022

Relapsed and Refractory B-cell Lymphoma Trial (CD19 CAR-T and CD19 CAR-DC)

Not yet recruiting
  • Relapsed and Refractory B-cell Lymphoma
  • CD19 CAR-T and CD19 CAR-DC
  • (no location specified)
Oct 16, 2022

B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

Recruiting
  • B-Cell Non Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia
  • anti-CD19 CAR T-cells
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023

B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • regimen with BTK inhibitor +Anti-CD19 CAR T cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Metabolically Armed CD19 CAR-T cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023

Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • allogenic CD19-CAR-NK cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (Metabolically Armed CD19 CAR-T cells)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Metabolically Armed CD19 CAR-T cells
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Feb 17, 2023

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

B-cell Lymphoma, B-cell Leukemia Trial in Kunming (anti-CD19 UCAR-NK cells)

Withdrawn
  • B-cell Lymphoma
  • B-cell Leukemia
  • anti-CD19 UCAR-NK cells
  • Kunming, Yunnan, China
    Kunming Hope of Health Hospital
Nov 27, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • CD19-targeted chimeric antigen receptor T-cell
  • Kaohsiung, Taiwan
  • +2 more
Oct 25, 2022

B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)

Recruiting
  • B-cell Lymphoma
  • ASCT+CAR-T Cell Infusion
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent Trial in Maywood (Fludarabine,

Active, not recruiting
  • B-Cell Acute Lymphoblastic Leukemia, Adult
  • +2 more
  • Maywood, Illinois
    Loyola University
Aug 11, 2022

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023